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30YEARS OF COST-EFFECTIVENESS ANALYSES:A
BIBLIOMETRIC REVIEW OF ARTICLES PUBLISHED INTHE
ECONOMIC AND MEDICAL LITERATURE: 1976–2005
Greenberg D1, Rosen AB2, Palmer JA3,Wacht O1, Neumann PJ3
1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2University of
Michigan Health Systems, Ann Arbor, MI, USA, 3Tufts-New England
Medical Center, Boston, MA, USA
Cost-effectiveness analysis (CEA) presenting a cost/QALY ratio is
considered the gold standard for economic evaluations in health
care. Despite the proliferation of CEA research, there has been no
detailed study focusing on the bibliometric properties of this
literature. To describe and analyze trends in publications and
co-authorship in the CEA literature from 1976–2005. We used
the Tufts-New England Medical Center registry of original CEAs
published through 2005 http://www.tufts-nemc.org/cearegistry/).
For each article we recorded the year of publication, journal’s
name, the number of contributing authors and their names.
Authors were assigned a credit based on their perceived contri-
bution to the study (1 credit point for the ﬁrst and last authors,
1/2 point for the second author, and 1/n credit points for all other
authors). We calculated the Author’s Contribution Index (ACI),
by dividing the total credit points by the number of studies
published by the same author. Approximately 1150 studies have
been published in 360 journals over the past 30 years, with an
increase in the number published annually from 18(26) in
1976–2000 to 138(46) in 2001–2005, p < 0.0001. The mean
number of contributing authors was 4.6(2.4) and increased
from 4.3(2.3) to 4.8(2.5), p < 0.0001 over that same time
interval. Medical journals were characterized by a higher number
of co-authors, as compared with the economic and health policy
literature: 4.7(2.4) vs. 4.2(2.1), p = 0.004. The lowest
number of co-authors (3.6) was in Value in Health and Medical
Decision Making, and the highest in Circulation (7.7). The most
proliﬁc authors were afﬁliated with Harvard and Tufts Universi-
ties. CONCLUSIONS: The CEA literature continues to prolifer-
ate. Co-authorship trends seem to follow the rapid increase in the
mean number of authors found in the health economics and
medical literature. Further research is needed to examine jour-
nals’ and authors’ concentration trends, and dissemination of
CEA results.
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THE DEVELOPMENT OF COST-EFFECTIVENESS INDICES
WITH EQUITY IMPLICATIONS FORTHE ECONOMIC
EVALUATION OF HEALTH CARE
Hu FC1,Wang JD2
1National Taiwan University Hospital,Taipei,Taiwan, 2National Taiwan
University,Taipei,Taiwan
The incremental cost-effectiveness ratio (ICER) with number of
dollars per quality-adjusted life year (QALY) has been exten-
sively used in cost-effectiveness analysis (CEA) for improving
efﬁciency in health care, but there is a lack of simple CEA
indicators to take the equity issue in health into consideration. In
this paper, by adjusting the ordinary ICERs with the quality-
adjusted life expectancy (QALE) of the age- and gender-matched
general population, we developed the CEA indicators based on
and/or weighted by relative health gap to improve the distribu-
tive justice. If we collect the quality of life and survival data to
estimate the QALY gained by a certain intervention for a speciﬁc
disease, then the CEA indicators based on and/or weighted by
relative health gain can also be developed to reduce the unin-
tended inequity. The proposed six new CEA indicators with
equity implications were empirically calculated for comparisons
among the diseases of end stage renal disease, acquired immune
deﬁciency syndrome, liver cancer, and breast cancer to demon-
strate their applicability.
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ACCOUNTING FORTHE PLACEBO RESPONSE IN
COST-EFFECTIVENESS ANALYSIS
McDonald HP1, Rebeira M1,Wright S2, Jaszewski B1
1Bayer Inc,Toronto, ON, Canada, 2GW Pharma Ltd, Salisbury, UK
Deﬁned as the psychophysiologic response associated with pla-
cebos, the placebo effect is of considerable interest to researchers
and clinicians. To ensure that study participants remain blinded
to treatment, a placebo must resemble the investigational
product in all aspects except for physiological activity: it should
have the same shape, colour, delivery mode, smell and taste. To
produce a placebo with all of these qualities, the development
cost and, thus, the daily cost of providing them to patients in a
clinical trial, can be signiﬁcant. Cost-effectiveness analyses
(CEAs) typically use efﬁcacy and safety data from RCTs. In fact,
phase 3 RCT data are often considered the most robust data
source in CEAs. By subtracting the clinical effect in the placebo
arm from the clinical effect in the active arm, CEAs remove the
placebo response from the effectiveness side of the equation.
However, the same method is not applied to the cost side: instead
of subtracting from the cost of active treatment, the cost of
placebo is ignored. This leads to an inaccurate estimation of the
incremental cost of treatment relative to the incremental effects
and, consequently, of the incremental cost-effectiveness ratio
(ICER). We propose a method whereby both the costs and effects
of placebo are incorporated into CEA. A CEA of Sativex in
oncology pain will be used to illustrate the proposed approach.
Results will be presented. In recognition of the clinical beneﬁt
that can be effected via the placebo response, RCTs have been
designed to measure this response and to deduce the true effect of
an active therapy. CEAs, which typically use data from these
RCTs, should adopt a similar approach. Economic analyses
should not only consider the effect but also the costs of placebo
to achieve a more accurate prediction of the ICER for an active
therapy.
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MEASURING ECONOMIC AND CLINICAL OUTCOMES
ASSOCIATEDWITHTELE-ICU MONITORING
Franzini L1, Sail K1,Wueste L2,Thomas E2
1University of Texas School of Public Health, Houston,TX, USA,
2University of Texas Medical School at Houston, Houston,TX, USA
OBJECTIVE: Patients in adult intensive care units (ICUs)
require multidisciplinary care that frequently result in substan-
tial morbidity, mortality, and costs. Telemedicine has been used
to provide remote intensivist monitoring for ICUs. We mea-
sured the economic and clinical outcomes associated with Tele-
ICU monitoring in 6 ICUs (5 hospitals) across the Houston
metropolitan area. METHODS: We assessed the cost and effec-
tiveness of Tele-ICU by comparing the economic and clinical
outcomes in the period after the full implementation of the
Tele-ICU (post period) with the economic and clinical outcomes
in the baseline period before the introduction of the Tele-ICU
(pre period). The cost analysis in this study adopts a hospital
perspective because the decision to implement a Tele-ICU is
made at the hospital or health system level. Costs were mea-
sured using hospital costs and the cost of operating the Tele-
ICU. Hospital costs were computed using average daily ICU
costs and ﬂoor costs for patients in each ICU during the two
study periods using individual patient data (4390 patients). ICU
and hospital length of stay (LOS) and ICU and hospital mor-
tality were obtained from chart reviews. RESULTS: Average
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daily per patient ICU costs across the six ICUs was $3060 and
$3663 in the pre and the post period respectively and the
average daily per patient ﬂoor costs was $1439 and $1551 in
the pre and the post period respectively. The average LOS
across the 6 ICUs increased from 4.5 to 5.3 days. There was no
signiﬁcant difference (p > 0.05) in the average mortality rate in
the pre and the post period across the 6 ICUs. CONCLUSION:
Unlike in previous studies, Tele-ICU monitoring increased hos-
pital costs and length of stay.
RESEARCH ON METHODS & CONCEPTUAL
PAPERS—Database Studies & Management
PMC13
USE OF POTENTIALLY INAPPROPRIATE PSYCHOACTIVE
MEDICATIONS AND FALLS IN U.S. NURSING HOME
RESIDENTS
Agashivala N,Wu W
St. John’s University, NY, NY, USA
Use of Potentially Inappropriate Psychoactive Medications
(PIPM) poses a serious threat of falls among elderly nursing
home residents. With this objective, the study was conducted to
identify the effects of PIPMs on falls among nursing home resi-
dents. The 2004 National Nursing Home Survey (NNHS) was
used as the data source. Logistic regression was performed to
ascertain the relationship between residents’ falls in the past 180
days and use of PIPM as per Beers’ criteria in the presence of
other risk factors. The data analysis was performed using SAS
9.1. The 2004 NNHS includes 1174 facilities consisting of 3868
males and 9639 females. The mean age of the residents was
80.5  12.97 years. The residents who fell were older than the
residents who did not fall (82.46 vs. 79.5 years, p < 0.0001).
Residents on PIPMs were at an increased risk of falling compared
to those who did not take PIPMs (odds = 1.295, p < 0.0001).
Residents suffering from mental disorders fell more compared to
the other group (odds = 1.316, p < 0.0001). Residents’ fall-risk
increased with an increase in the number of impaired ADLs
(odds = 1.158, p < 0.0001). The fall-risk also increased with
advance of age (odds = 1.017, p < 0.0001). Use of bedrails had a
protective effect on residents fall-risk (odds = 0.652, p < 0.0001).
In addition to these factors, male gender (odds = 1.247,
p < 0.0001) and white race (odds = 1.485, p < 0.0001) were also
signiﬁcant risk factors. Among facility factors, being a non-proﬁt
facility (n = 467) was associated with a higher risk of falls
(odds = 1.133, p < 0.0001). Prevention of falls in elderly nursing
home residents remains a challenge. PIPMs are still prescribed to
the elderly nursing home residents. Access to appropriate psy-
choactive medications should be ensured. Residents with the
identiﬁed risk factors should be closely monitored. Further
research should be pursued to evaluate the impact of medications
in other therapeutic categories and facility factors on falls.
PMC14
EXPLORING CANDIDATE DIFFERENCES BETWEEN DRUG
COHORTS PRIORTO EXPOSURE:A SYSTEMATIC APPROACH
USING MULTIPLE OBSERVATIONAL DATABASES
Ryan PB, Powell GE
GlaxoSmithKline, Research Triangle Park, NC, USA
OBJECTIVES: To develop a systematic approach using disparate
observational databases for identifying pre-exposure differences
in condition incidence across drug cohorts. A case study to
examine the utility of the method was conducted, comparing
dutasteride with ﬁnasteride. METHODS: Two disparate data-
bases an electronic health record (EHR) and an administrative
claims database were used for analysis. We applied an
unmatched cohort design to each source, capturing all persons
within the two exposed populations. For all conditions, we cal-
culate unadjusted incidence rates prior to exposure for each
cohort and the associated incidence rate ratios (IRR) between
cohorts. Three different IRR estimates were calculated using
unique deﬁnitions of person-time: ‘6 months’ prior to exposure,
any time ‘before’ exposure, and ‘variable’ time based on length of
exposure. Each method used statistical signiﬁcance of the IRR as
the threshold for identifying ‘candidate differences’ (CD). A com-
posite threshold requiring signiﬁcance across both sources was
also used. RESULTS: Using the ‘6 months’ metric, 194 CDs
within the EHR and 469 within the claims database were iden-
tiﬁed, with 108 conditions occurring in both sources. Expert
review found the combined list contained all concepts previously
hypothesized as important to consider when designing a
dutasteride-ﬁnasteride study, as well as 10 conditions not
hypothesized but deemed important for any evaluation, 40 unex-
pected pre-exposure conditions that warranted further consider-
ation, and 10 terms that added no value. There was good
concordance across metrics, with 70 of 129 ‘before’ CDs and 95
of 161 ‘variable’ CDs matching the ‘6 months’ results. CON-
CLUSIONS: Exploratory analysis of pre-exposure cohort differ-
ences can enhance design of observational evaluation studies,
guiding researchers to develop their conceptual model to assess
the relationship between treatment and outcome by identifying
potential sources of sample selection bias. Using multiple data
sources allows independent veriﬁcation of exploratory ﬁndings,
raising conﬁdence that CDs identiﬁed bear consideration.
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DETERMININGTHE MECHANISM OF MISSING DATA IN
INCOMPLETE DATASETS
Whillans F1,Tarride JE2, Blackhouse G2, Hopkins R2, Goeree RA2
1Dymaxium Inc,Toronto, ON, Canada, 2McMaster University,
Hamilton, ON, Canada
OBJECTIVES: In any study involving individual level data, the
problems associated with incomplete observations are an
obstacle to analysis. For this reason methods have been devel-
oped to complete these datasets. Multiple imputation is consid-
ered the most robust method of handling missing data, however
it is also the most complex and computationally intensive.
Whether multiple imputation is needed depends on the mecha-
nism of the missing data. For example, if data is missing com-
pletely at random simpler methods can be used. For this reason,
we conduct an analysis to inform the appropriate imputation
method by identifying the mechanism of missing data.
METHODS: To determine the mechanism of missing data we ﬁt
a probit model to a dataset from a study comparing the use of
Endovascular Repair (EVAR) versus the use of Open Surgical
Repair (OSR) in repairing Abdominal Aortic Aneurisms. From
this we determined the appropriate method to complete the
dataset. We then ran a sensitivity analysis on the different
methods to determine the potential consequence of utilizing the
inappropriate method. RESULTS: The results of the probit
model indicated that the dataset had data which was missing at
random and thus the missingness is predictable by observables in
the dataset. This implied that the most appropriate method is
imputation by stochastic regression or multiple imputation(the
stronger of the two methods). The sensitivity analysis, however,
showed no statistically signiﬁcant difference between the two
methods in terms of QALYs—total QALY difference between
EVAR and OSR: -0.09952(-0.13202,-0.0670) for SR and
-0.0866(-0.12344,-0.04977) with signiﬁcant deviations from
other methods. CONCLUSIONS: This study demonstrates the
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